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Abstract
Background: Bright white light has been successfully used for the treatment of depression. There
is interest in identifying which spectral colors of light are the most efficient in the treatment of
depression. It is theorized that green light could decrease the intensity duration of exposure
needed. Late Wake Treatment (LWT), sleep deprivation for the last half of one night, is associated
with rapid mood improvement which has been sustained by light treatment. Because spectral
responsiveness may differ by age, we examined whether green light would provide efficient
antidepressant treatment in an elder age group.
Methods: We contrasted one hour of bright green light (1,200 Lux) and one hour of dim red light
placebo (<10 Lux) in a randomized treatment trial with depressed elders. Participants were
observed in their homes with mood scales, wrist actigraphy and light monitoring. On the day prior
to beginning treatment, the participants self-administered LWT.
Results: The protocol was completed by 33 subjects who were 59 to 80 years old. Mood
improved on average 23% for all subjects, but there were no significant statistical differences
between treatment and placebo groups. There were negligible adverse reactions to the bright
green light, which was well tolerated.
Conclusion: Bright green light was not shown to have an antidepressant effect in the age group
of this study, but a larger trial with brighter green light might be of value.
Background
Bright white light has been shown to suppress melatonin,
shift circadian rhythms and alleviate depression. Evidence
suggests that green light may have effects similar to those
of white light but could be more efficient [1-4]
Recent studies have suggested that lower photon densities
of blue light are required to suppress melatonin or to shift
circadian phase than green, yellow, or red light [5-8]. It
has been suggested that ganglion cells supplying the retin-
ohypothalamic tract may be particularly responsive to
blue light because they contain the blue-light-absorbing
photopigment, melanopsin [9,10]. Retinohypothalamic
transmission is key to light suppression of melatonin and
to light-induced circadian phase shifting. However, there
are reasons for skepticism that blue light is the best choice
Published: 09 November 2005
BMC Psychiatry 2005, 5:42 doi:10.1186/1471-244X-5-42
Received: 13 May 2005
Accepted: 09 November 2005
This article is available from: http://www.biomedcentral.com/1471-244X/5/42
© 2005 Loving et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 8
(page number not for citation purposes)
BMC Psychiatry 2005, 5:42 http://www.biomedcentral.com/1471-244X/5/42for light treatment of depression. The role of the retinohy-
pothalamic tract in the antidepressant effects of bright
light has not been fully established. The retinohypotha-
lamic tract can be stimulated by light in the absence of
melanopsin, suggesting an ancillary role for rods or cones
which may be more sensitive to green light [11]. Indeed,
the actual empirical peak wavelength for stimulation of
melanopsin cells was about 500 nm (blue-green),
although fitting an opsin curve to the data yielded inter-
polated blue peaks around 470–480 nm [12,13]. A single
opsin curve cannot be accurately explanatory if melanop-
sin, rods, and cones are all involved. In some studies,
adjustment of retinal sensitivity spectra for attenuation of
blue light by the ocular lens may have suggested a greater
advantage for blue light than was empirically observed
with corneal illumination [5]. Indeed, in older subjects,
whose yellowing lens increasingly attenuates blue light,
green light might be as effective as blue light in suppress-
ing melatonin [14-16]. The practical advantage of blue
light may also be exaggerated by expressing sensitivity in
photon densities, since blue photons contain more energy
as compared to green or red. The risks of blue light are
greater [17]. For these considerations, the benefits/risks
ratio could be better with green light than with blue light,
possibly better than with most white light. Previous stud-
ies of green light have suggested positive benefits with
modest brightness, e.g., 200–2500 lux [4,18,19].
The mood-improving effects of one night of partial sleep
deprivation are enhanced by subsequent daily use of light
treatment. Our laboratory's earlier studies, [20,21] the
Praskos' study, [22] and the work of Neumeister et al.,
[23] Loving, [24] and Bloching [25] all indicated that Late
Wake Treatment (LWT), when combined with bright
light, produces remarkable antidepressant responses,
demonstrated by dramatic contrasts between bright light
and placebo. Considering the evidence that LWT may
accentuate the contrast of bright light and placebo, we
believed LWT would add to the potential light treatment
effect anticipated in this study.
In a previous study to be reported separately, we found no
significant benefit of bright white light for elderly
depressed outpatients . This study sought to determine if
light resistance in the 60–79 year age range could be over-
come with bright green light. Specifically, we ran a 4-week
clinical trial of morning bright green light versus dim red
placebo light, as an adjunctive antidepressant treatment.
Besides changing the active treatment from 8,500 lux
white fluorescent light to 1,200 lux green LED light, this
study differed from our previous clinical trial of depressed
elders by focusing on morning treatment regardless of the
subject's chronotype (circadian adjustment) and by rand-
omizing active treatment immediately after intake, with-
out baseline recording. In this study, no hormone data
were collected.
Methods
Recruitment for depressed individuals, age 60–79 years,
was conducted by advertising and public presentations,
from February 2004 to January 2005. Written informed
consent was obtained from each participant in accordance
with the guidelines set forth by the Declaration of Hel-
sinki. The study protocol and consent form were approved
by the UCSD Human Research Protection Program. In
addition, those participants who were being treated for
depression by either a physician or counselor were
requested to obtain the written agreement of the therapist
for the study, to assure that there was no interference with
ongoing treatment and treatment responsibility. Patients
were encouraged to continue ongoing treatment during
the study, with the assumption that psychotherapy and
medication effects over an interval of 4 weeks were likely
to be small and randomized between groups.
For enrollment in the study, a Geriatric Depression Scale
(GDS) score of 11 (indicating probable major depression)
[26] was required. Meeting full DSM-IV criteria for current
major depressive disorder was not required, because
many aging depressed people need treatment without
meeting criteria for major depressive disorder [27]. As a
history of mania appears to predict a greatly increased risk
of a manic switch during bright light treatment, any vol-
unteer with a history of mania was excluded [28]. Volun-
Spectrophotometric measures of illumination are shown comparing daylight with the green and red tre tment lightsFigure 1
Spectrophotometric measures of illumination are shown 
comparing daylight with the green and red treatment lights. 
Sunlight was measured with the photometer pointed 
towards the horizon (and shaded from direct sun) near noon 
on a clear sunny day (32.85 North latitude, 2/2/05). Green 
light was measured at 2 feet with the photometer oriented 
towards the center of the box. The red light was measured 
with the photometer adjacent to the diffuser, because at 2 
feet, the illumination was too dim to be plotted on the same 
scale. The irradiance scale was arbitrary (uncalibrated) but 
identical for the three measures.
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treatment would add little were also excluded. For exam-
ple, if they were outdoors for more than an hour at times
of potential light triggered circadian rhythm shifts, that is
during morning or evening hours. The Structured Clinical
Interview for DSM-IV Axis I Disorders (Non-patient Edition)
[29] was administered during the assessment period.
Subjects were then randomized into one of two treatment
groups: A) 1,200 lux bright green light or B) 10 lux dim-
red-light placebo. Computerized randomized assignment
within blocks, using sealed envelopes, was stratified for
age below or ≥ 68 years, and baseline GDS score below or
≥ 16. One hour of treatment was self-administered within
one hour of awakening. Subjects were instructed to place
the light box at eye level and to sit so their eyes were 24"
from the light box. Both red (SunBox Company, Gaithers-
burg, MD) and green (Apollo Health, Orem, UT) light
boxes were specially built for the study. They each used
light emitting diodes (LED) as the light source (See Figure
1). Both light sources were enclosed in standard light
treatment boxes, approximately 18" × 24" × 4", with a
clear light diffuser panel on the front.
We employed dim red light as a placebo, reasoning that
because the light was dim and because the red part of the
spectrum may be relatively inactive biologically [5] there
would be no substantial biological effect. Fortunately,
claims by others of red-light benefits allowed us to tell
volunteers, without deception, that some people think
that red light is active, even though we are skeptical. In
this way, we attempted to keep subjects blind to treatment
expectations.
During the four week protocol, the volunteers completed
sleep-activity logs daily. They continuously wore an Actil-
lume wrist monitor (Ambulatory Monitoring Inc., Ards-
ley, N.Y.) to record sleep-wake data and illumination
data.
To test the benefits of partial sleep deprivation, on the ini-
tial night of the research protocol, we asked volunteers to
awaken themselves 4 hours after going to bed and to
remain awake for the second half of the night. They were
asked to call our telephone answering machine every half
hour to confirm that they had been awake for that time
period. In a previous study, we found such home sleep
deprivations work well without complication [24], but in
our previous study of depressed elderly, few could success-
fully comply.
To assess subject expectations for the two treatments,
measures were taken at the beginning and end of treat-
ment, using 100 mm visual analog scales for both mood
and sleep improvement. The initial rating was obtained
after the subject was randomized and had seen the light
they would be using but before the first actual treatment.
A final assessment was obtained on the last day of the
study.
Four weeks of treatment were carried out with weekly
symptom assessments and continuous wrist recordings of
activity and illumination exposure. The investigators vis-
ited subjects weekly to assure their safety and their com-
pliance with the study, to administer and collect rating
forms, and to transfer data from the Actillume recorders.
A final symptom and circadian assessment was completed
in the last 48 hours of the 4-week randomized treatment.
Two-week and 4-week follow-up assessments were
obtained.
In addition to daily log sheets used to record activity, sleep
behaviors, and visual analog self ratings of mood, the sub-
jects completed a weekly GDS [26] and a Systematic
Assessment for Treatment Emergent Events (SAFTEE) [30]
symptom scale. GDS ratings were also completed at the
usual time of awakening after the half-night sleep depriva-
tion. Further mood measurements were made at baseline
and end-of-treatment using the SIGH_SAD_SR, a self-rat-
ing form including the Hamilton Depression Rating Scale
(HDRS, 17 items used) and atypical items previously
shown to be responsive to light treatment [31]. Addition-
ally, when a graduate student was available, a blind HDRS
rating interview was obtained at baseline and in the last
week of the study.
Records from the Actillume monitor indicating total activ-
ity, sleep-wake, and log10[lux] were fitted to cosine curves
for each subject. The mesors or fitted cosine means were
examined, as well as the acrophases which indicate the
time of day of the fitted peak.
Results
Sixty-one potential participants signed consents and were
initially screened. Twenty-eight candidates did not meet
GDS criteria, and 33 subjects completed the protocol, 5
males and 28 females. Bright green light treatment was
received by 17 subjects, and 16 received dim red light pla-
cebo. The mean age for those completing the study was
67.7 years (SD = 6.35) and ranged from 59 to 80.
Based on the SCID interviews, DSM IV Axis I diagnoses for
the sample were Major Depressive Disorder (N = 30) and
Minor Depressive Disorder (N = 1). Two subjects had
GDS ≥ 11 but did not meet SCID criteria for any Axis I
diagnosis. None of the subjects met criteria for DSM IV
Seasonal Trend. The characteristics of these depressed sub-
jects ranged from single episodes to chronic recurrent con-
ditions and varied in severity. This added to the general
applicability of the treatments.Page 3 of 8
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being seen by a psychotherapist during research treat-
ment. Of these 13, 7 received bright green light and 6
received dim light. In all 13 cases, treatment was stable
during the study. Antidepressants medication was used by
13 of the subjects (5 bright green light, 8 dim light). Other
prescription medications used by participants were;
antianxiety (2), cardiac (7), antihypertensive (11), analge-
sic (6), hypnotic (8), thyroid (9), hormone replacement
therapy (9), diabetes drugs (1), cholesterol-lowering com-
pounds (12). Nine subjects received both psychotherapy
and psychiatric medication, of whom 5 received bright
green light and 4 received dim light. The 5 subjects receiv-
ing bright green light had no medication changes, and of
the 4 dim light subjects, 2 had minor medication changes,
one increased fluoxetine from 20 mg to 40 mg per day at
week 2 and one reduced citalopram from 20 mg to 10 mg
only for the second week of the study.
For the 33 subjects who completed the protocol, groups
assigned to active and control light treatment were bal-
anced in age and severity of depression (see Table 1).
Expectations for sleep and mood effects of light treatment
are shown in Table 2. A repeated-measures MANOVA as
well as a one-way ANOVA of change scores showed no dif-
ference in the sleep and mood expectations between the
bright and dim treatment groups either before or after
treatment, suggesting that the dim red light was an active
control which balanced expectations.
Sleep changes
Sleep parameters were not statistically different between
the green light treatment group and the red light placebo
group. There was no significant effect on sleep onset time
or sleep offset time, nor did total sleep time vary signifi-
cantly by treatment. The total amount of Actillume-esti-
mated sleep was balanced at baseline and not significantly
affected by treatment assignment. The baseline, initial
week, estimate of total sleep during the nocturnal period
was 332 minutes. During the final week the estimate of
total sleep during the nocturnal period was 347 minutes.
The sleep efficiencies for the initial week and the final
week were 75.2 and 74.5 respectively. Wake after sleep
onset did not vary at baseline or at the end of treatment.
The number of awakenings during the night and the sleep
latency did not vary significantly either at the beginning or
end of treatment.
Mood improvement
Mean mood scores for the different groups at each meas-
urement point are shown in Table 3. Subjects' mood
improved under both treatments. The average GDS score
improved by 7 points (an average of 23%). There were no
significant treatment differences in GDS improvement by
ANCOVA. The average HDRS17 (extracted from the self-
rated SIGH-SAD-SR) improved by 7 points. Improve-
ments following wake treatment were not statistically sig-
nificant. There were no significant treatment differences in
HDRS17 improvement or atypical scores. Blind HDRS17
ratings, when available, were consistent with the self-rat-
ing (HDRS17) scores. Power analysis estimated 80%
power to detect a large effect size of 0.51 in either the GDS
or self-rated HDRS17.
Adverse reactions
Participants experienced no psychiatric hospitalizations,
suicide attempts, or deaths during the study or follow-up.
There were no incidents of mania or hypomania during
the light treatment or during follow-up.
Table 2: Expectations for Improvement in Sleep and Mood
100 mm Visual Analog Scale, 0 = Worse 100 = Better
Measure Mood Sleep
Light Green Red Green Red
Time Initial Final Initial Final Initial Final Initial Final
N 16 16 14 14 16 16 14 14
Mean 76.3 69.6 83.4 70.1 71.7 71.8 78.9 64.1
SD 18.0 13.6 12.5 20.0 20.9 9.7 12.9 24.0
Table 1: Stratification by Age and Depression Severity
Age-Depression Severity Group Bright Dim Total
Age < 68, GDS < 16 0 0 0
Age < 68, GDS ≥ 16 10 10 20
Age ≥ 68, GDS < 16 2 2 4
Age ≥ 68, GDS ≥ 16 5 4 9
Total 17 16 33Page 4 of 8
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examined for adverse reactions to both of the light treat-
ments. Ninety-six individual symptoms were evaluated
for change during the light treatment period. To improve
the stability of measurement, symptoms were grouped
into 17 SAFTEE-defined categories, which were tested
with Wilcoxon's Signed Rank Test. The results of these
group tests are contained in Table 4. The symptom groups
for Eyes, Urination, Muscle/Bone, and Other all improved
in the bright green light condition. The symptom groups
for Mouth/Teeth, Gynecology, and Muscle Bone
improved in the dim red light condition. No symptom
groups worsened under either light condition The "Other"
category contains a large number of mood related items.
There were no significant contrasts in SAFTEE changes
between treatments.
Acrophase changes
The two treatment groups had no significant differences in
Actillume-recorded activity, sleep, or light exposure at
baseline (see Table 5), that is, they were essentially identi-
cal in these measures. The fitted peaks (acrophases) of the
24-hour rhythms of activity, sleep, and light exposure
were all later in the last week of treatment than the first
Table 4: SAFTEE Symptoms, Mean Scores for Beginning and End of Light Treatment with Wilcoxon Signed Ranks Test
Light Condition Bright Dim
Symptom 
Category
Baseline Post Treatment p Baseline Post Treatment p
Head 5.62 4.94 .078 5.31 5.25 .760
Eyes 9.41 7.41 .009 10.19 8.38 .212
Ears 5.12 5.06 .739 5.94 6.06 .661
Mouth/Teeth 8.18 7.53 .754 9.19 8.31 .043
Nose/Throat 7.35 6.59 .052 7.62 6.81 .283
Chest 8.64 8.18 .231 7.81 7.88 .666
Heart 2.18 2.53 .063 2.12 2.62 .480
Stomach/
Abdomen
5.88 5.59 .474 5.38 5.69 .144
Bowel 8.35 7.59 .192 9.62 8.62 .305
Appetite 6.76 6.47 .475 7.50 6.62 .117
Urination 7.71 6.76 .042 7.12 7.25 .856
Gynecology 3.47 3.71 1.00 5.19 2.25 .026
Genital/Sexual 5.06 5.35 .799 6.38 4.69 .074
Muscle/Bone 7.47 6.00 .011 6.25 4.81 .016
Walking/Moving 9.24 8.12 .065 8.62 8.62 .152
Scalp/Skin 5.82 5.76 .887 6.44 5.81 .232
Other 33.76 24.12 .001 27.81 23.06 .052
Table 3: GDS and HDRS Scores by Week by Light Condition Mean (SD) N
Light Condition Bright Light Dim Light
Baseline 20.5 (5.19) 17 20.1 (3.98) 16
After Wake Treatment 16.1 (7.33) 17 18.5 (4.81) 16
Treatment week 1 19.4 (5.51) 16 19.5 (5.26) 14
Treatment week 2 15.5 (7.57) 15 15.6 (5.50) 16
Treatment week 3 13.3 (6.72) 16 15.9 (5.92) 16
Treatment week 4 12.1 (6.25) 17 14.0 (6.30) 16
Two-week follow-up 13.5 (7.53) 17 10.7 (6.89) 11
Four-week follow-up 12.4 (7.66) 16 10.3 (7.07) 10
3-Month follow-up 11.6 (7.59) 13 15.8 (6.94) 6
HDRS 17 Self Report – Baseline 19.1 (4.13) 17 17.0 (4.80) 16
HDRS 17 Self Report – Final 11.4 (3.94) 17 10.8 (5.01) 16
Blind HDRS 17 – Baseline 18.0 (4.87) 13 17.9 (6.34) 14
Blind HDRS 17 – Final 11.4 (5.11) 13 10.5 (6.73) 14Page 5 of 8
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red light treatments were significant (see Table 6).
Although an objective measure of compliance was not
available, examination of the light records from the Actil-
lume data suggested a high degree of compliance with
treatment. The self reports of treatment time and duration
were almost entirely consistent with instructions. The
absence of dropouts and the compliance of participants
with wearing Actillumes and completing logs and ques-
tionnaires also suggested that compliance with treatment
was probably high.
Green light acceptance
The bright green light boxes were well tolerated by the
subjects. There was no need to reduce intensity as there
sometimes is with bright white light. There was no com-
plaint of eye strain or discomfort. Some of the subjects
who had experience with bright white light either before
or after the study expressed a preference for the green
light.
Discussion
Bright green light treatment did not increase symptom
complaints in the 60–79 year old age group and caused
only negligible adverse effects. Although no statistically
significant advantages of the 1,200 lux green light were
found, the trend in self-ratings favored the green light, and
the effect sizes on self-rating depression scales were com-
parable to those in many trials of 8+ weeks of antidepres-
sant drugs [32]. Most antidepressants drug trials are
planned on a larger scale to achieve significance even with
small effect sizes (which may be all that the antidepres-
sant achieves). The current study only had power to detect
a large effect, which was not observed.
Our observations of the benefits of wake treatment were
comparable to the findings in our previous study, again
suggesting that wake therapy might not be effective in this
age group. Part of the reason is certainly the difficulty of
people in this age group in successfully remaining awake
for the required interval. It has also been suggested that
sleep deprivation may actually interfere with antidepres-
sant treatment for the elderly, [33] which may possibly
explain the lack of success of this trial.
Treatments were balanced by age and severity of depres-
sion, validating that the stratified randomization proce-
dures were successful. The balancing of participant
expectations and the similarity of blind and self-rated
HDRS-17 scores indicate that the difficulties in blinding
light treatment probably had no influence on the out-
come.
There are several possible explanations for the antidepres-
sant effects found from both of the light treatments in this
study. The placebo effect must be considered in all clinical
research. There were positive expectations for both treat-
ments for both sleep and mood. The socialization and
daily structure provided by the study may have lead to
Table 6: Acrophase Changes (minutes) by Light Condition Mean (SD) N
Acrophase Change (minutes) 
Baseline minus Final
Bright green light Dim red light p (ANOVA)
Light -34.05 (52.32) 15 -5.02 (53.25) 16 0.14
Activity -49.20 (106.75) 16 -5.35 (54.30) 16 0.15
Sleep -34.63 (59.04) 16 -4.48 (67.75) 15 0.20
Note: Negative change indicates a later (delayed) acrophase at the end of treatment.








Green Mean 12.42 14:05 1.08 13:29 .27 02:49
N 16 16 16 16 16 16
S.D. 3.77 02:13 .22 01:26 .06 01:46
Dim Red Mean 12.52 14:39 1.03 14:07 .27 03:24
N 16 16 16 16 16 16
S.D. 3.80 01:38 .25 01:33 .05 01:49
p (ANOVA) .939 .425 .488 .233 .775 .373Page 6 of 8
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effect of green light, but not in this age group. Yellowing
of the lens in some elders may tend to attenuate light of
500 nm, though to a lesser extent than shorter wave-
lengths [15]. The lack of a more distinct advantage for the
green light in this study may have been due to inadequate
intensity and/or duration of treatment or partial light
resistance in this age group. The failure to demonstrate
phase advances in actigraphic measures with the green
light would be consistent with inadequate green light
intensity, light resistance, or poorer compliance than we
have otherwise appreciated.
In this our first study with LED green light treatment, we
selected a modest intensity of treatment, considerably less
than the green component of sunlight and much less than
broad-band visible illumination of sunlight (Figure 1).
On the one hand, successful white light treatment has
often required much more than 1,200 lux. On the other
hand, even 400 lux of green light augmented citalopram
treatment in a previous study, [19] though a limitation of
that study was a possible confounding of the light effect
with an earlier waking time. Since the green light was so
well-tolerated, a larger-scale trial with somewhat brighter
green light would appear safe and might well demonstrate
a significant benefit.
Conclusion
This trial of moderate bright green light contrasted with
dim red light placebo did not demonstrate significant dif-
ference in mood, sleep or activity measures in this age
group. The trail of Late Wake Treatment similarly, did not
produce significant improvement in mood measures.
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